Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study
- PMID: 16868063
- DOI: 10.1210/jc.2005-2250
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study
Abstract
Context: The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome. All these studies are, however, characterized by a short to medium period of treatment.
Objective: Our objective was to investigate the long-term effects of these therapies.
Design and setting: We conducted a prospective, randomized, placebo-controlled trial at a medical center.
Patients: Of 80 overweight-obese women with PCOS, 76 completed the study.
Interventions: Patients were placed on a hypocaloric diet for the first month and then on a hypocaloric diet plus placebo, metformin (850 mg, orally, twice a day), flutamide (250 mg, orally, twice a day), or metformin plus flutamide for the subsequent 12 months (20 subjects in each group).
Main outcome measures: We assessed clinical features, computerized tomography measurement of fat distribution, androgens, lipids, and fasting and glucose-stimulated glucose and insulin levels at baseline and after 6 and 12 months of treatment.
Results: After 6 months, compared with placebo, flutamide further decreased visceral/sc fat mass (P = 0.044), androstenedione (P < 0.001), dehydroepiandrosterone sulfate (P < 0.001), and hirsutism score (P < 0.001), whereas metformin further increased frequency of menstruation (P = 0.039). After 12 months, flutamide maintained the effects observed after 6 months on visceral/sc fat mass (P = 0.033) and androstenedione (P < 0.001), whereas it produced an additional decrease in dehydroepiandrosterone sulfate (P = 0.020) and hirsutism score (P = 0.019); metformin further improved the menstrual pattern (P = 0.013). Moreover, after 12 months, flutamide improved more than placebo the menstrual pattern (P = 0.008), glucose-stimulated glucose levels (P = 0.041), insulin sensitivity (P < 0.001), and low-density lipoprotein cholesterol levels (P = 0.003), whereas metformin decreased glucose-stimulated insulin levels (P = 0.014). The combination of the two drugs maintained the specific effect of each of the compounds, without any additive or synergistic effect.
Conclusions: These findings add relevance to the usefulness of metformin and flutamide in the treatment of dieting overweight-obese PCOS women and provide a rationale for targeting different therapeutic options according to the required outcomes in the long term.
Similar articles
-
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74. doi: 10.1210/jcem.85.8.6738. J Clin Endocrinol Metab. 2000. PMID: 10946879 Clinical Trial.
-
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.Clin Endocrinol (Oxf). 2004 Feb;60(2):241-9. doi: 10.1111/j.1365-2265.2004.01973.x. Clin Endocrinol (Oxf). 2004. PMID: 14725687 Clinical Trial.
-
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.J Obstet Gynaecol Res. 2013 Apr;39(4):806-13. doi: 10.1111/j.1447-0756.2012.02051.x. Epub 2012 Dec 21. J Obstet Gynaecol Res. 2013. PMID: 23279603 Clinical Trial.
-
An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.BMJ Open. 2015 Mar 27;5(3):e007280. doi: 10.1136/bmjopen-2014-007280. BMJ Open. 2015. PMID: 25818277 Free PMC article. Review.
-
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.Arch Gynecol Obstet. 2023 May;307(5):1347-1376. doi: 10.1007/s00404-022-06549-6. Epub 2022 Apr 18. Arch Gynecol Obstet. 2023. PMID: 35434762 Review.
Cited by
-
Age-Dependent Changes in the Effects of Androgens on Female Metabolic and Body Weight Regulation Systems in Humans and Laboratory Animals.Int J Mol Sci. 2023 Nov 21;24(23):16567. doi: 10.3390/ijms242316567. Int J Mol Sci. 2023. PMID: 38068890 Free PMC article. Review.
-
Agaricus Subrufescens ameliorates ovarian dysfunction and regulates altered biochemical parameters in rats with Letrozole induced polycystic ovarian syndrome.J Ovarian Res. 2023 Nov 22;16(1):221. doi: 10.1186/s13048-023-01311-1. J Ovarian Res. 2023. PMID: 37993900 Free PMC article.
-
Association between sex steroid hormones and subsequent hyperglycemia during pregnancy.Front Endocrinol (Lausanne). 2023 Sep 8;14:1213402. doi: 10.3389/fendo.2023.1213402. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37766683 Free PMC article.
-
Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.EClinicalMedicine. 2023 Aug 9;63:102162. doi: 10.1016/j.eclinm.2023.102162. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37583655 Free PMC article.
-
Cold-Induced Reprogramming of Subcutaneous White Adipose Tissue Assessed by Single-Cell and Single-Nucleus RNA Sequencing.Research (Wash D C). 2023 Jun 28;6:0182. doi: 10.34133/research.0182. eCollection 2023. Research (Wash D C). 2023. PMID: 37398933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical